SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2018-10-26
DOI
10.1080/17425255.2018.1541348
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes
- (2018) Priska Stahel et al. CANADIAN JOURNAL OF CARDIOLOGY
- Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care
- (2018) Thomas Danne et al. Diabetes Technology & Therapeutics
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis
- (2018) Jian Li et al. ENDOCRINE JOURNAL
- Hypertension and Diabetes MellitusNovelty and Significance
- (2018) Vasilis Tsimihodimos et al. HYPERTENSION
- Prevalence of Diagnosed Diabetes in Adults by Diabetes Type — United States, 2016
- (2018) Kai McKeever Bullard et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
- (2018) Tricia Santos Cavaiola et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels
- (2017) Harold E. Bays et al. Journal of Clinical Lipidology
- A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
- (2017) Seon-Ah Cha et al. Lipids in Health and Disease
- Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus
- (2017) Jian Li et al. MEDICINE
- Angiopoietin-like 3 in lipoprotein metabolism
- (2017) Sander Kersten Nature Reviews Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors: are they safe?
- (2017) Sebastian Filippas-Ntekouan et al. POSTGRADUATE MEDICINE
- Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
- (2017) Maryam Khavandi et al. Current Cardiology Reports
- SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
- (2017) Leonardo Spatola et al. Diabetes Therapy
- SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
- (2017) Leonardo Spatola et al. Diabetes Therapy
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes
- (2017) Marshall B. Elam et al. JAMA Cardiology
- Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
- (2016) François Briand et al. DIABETES
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
- (2016) Giuseppe Daniele et al. DIABETES CARE
- Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies
- (2016) Vasilios Tsimihodimos et al. Expert Opinion on Drug Metabolism & Toxicology
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- (2016) T. D. Filippatos et al. EXPERT OPINION ON PHARMACOTHERAPY
- Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D
- (2016) Mohamed Abu-Farha et al. Lipids in Health and Disease
- The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
- (2016) Matthias Kern et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pharmacological management of diabetic dyslipidemia
- (2016) T. D. Filippatos et al. Expert Review of Clinical Pharmacology
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
- (2015) Nobuya Inagaki et al. ADVANCES IN THERAPY
- Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal ObesitySignificance
- (2015) Jan Borén et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- New insights into the pathophysiology of dyslipidemia in type 2 diabetes
- (2015) Marja-Riitta Taskinen et al. ATHEROSCLEROSIS
- Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes
- (2015) B. Bode et al. DIABETES OBESITY & METABOLISM
- Pathophysiology of diabetic dyslipidaemia: where are we?
- (2015) Bruno Vergès DIABETOLOGIA
- Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
- (2015) Aurora Merovci et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
- (2014) N. Katsiki et al. CURRENT MEDICINAL CHEMISTRY
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men
- (2013) J. Wang et al. JOURNAL OF INTERNAL MEDICINE
- Small High-Density Lipoprotein (HDL) Subclasses are Increased with Decreased Activity of HDL-Associated Phospholipase A2 in Subjects with Prediabetes
- (2013) Theodosios D. Filippatos et al. LIPIDS
- Regulation of the human Na+-dependent glucose cotransporter hSGLT2
- (2012) Chiara Ghezzi et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia
- (2012) Janet D. Sparks et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
- (2012) Aneta Otocka-Kmiecik et al. PROGRESS IN LIPID RESEARCH
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
- (2011) Giovanni Musso et al. ANNALS OF MEDICINE
- Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects
- (2011) Marja-Riitta Taskinen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
- (2011) Dimitri P. Mikhailidis et al. Current Vascular Pharmacology
- Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes
- (2010) Bruno Vergès ATHEROSCLEROSIS
- Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?
- (2010) M. Rizzo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Management of dyslipidemia in people with type 2 diabetes mellitus
- (2010) Fredrick L. Dunn REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome
- (2008) K. G. Lagos et al. LIPIDS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now